CompanyJUNSNasdaqJupiter, FL

Jupiter Neurosciences, Inc.

Jupiter Neurosciences develops JOTROL, an oral resveratrol formulation targeting neuroinflammation.

SEC EDGAR ClinicalTrials.gov

SCHEDULE 13GSep 22Latest SEC filing

Sep 4Latest story

September 2026

Jupiter Neurosciences files Form D for $774,787 private offering

Sep 4FinancingJupiter Neurosciences, Inc.

August 2026

Jupiter Neurosciences executives forgive $875,315 in accrued pay

Aug 27PartnershipJupiter Neurosciences, Inc.

Jupiter Neurosciences prices $2.0 million registered direct offering at $6.50 per share

Aug 24FinancingJupiter Neurosciences, Inc.

July 2026

Jupiter Neurosciences sells $3.6M in stock to Yorkville under equity line

Jul 28FinancingJupiter Neurosciences, Inc.

Jupiter Neurosciences signs U.S. license deal with PharmAla for ALA-002

Jul 21PartnershipJupiter Neurosciences, Inc.

June 2026

Jupiter Neurosciences adds health economist Tomas Philipson to board

Jun 30PeopleJupiter Neurosciences, Inc.